Clinical Trial

A Prospective Single-Arm Study（NCLDR）

Study acronym: NCLDR
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
To investigate the safety and efficacy of low-dose radiotherapy combined with chemotherapy and immunotherapy as neoadjuvant therapy for locally advanced oral squamous cell carcinoma (OSCC), and to explore whether low-dose radiotherapy can induce cross-presentation of tumor-specific antigens, enhance lymphocyte infiltration into the tumor microenvironment, and thereby amplify tumor-specific immune responses, ultimately improving the therapeutic outcomes of neoadjuvant chemoimmunotherapy.
Trial Details
NCT Number NCT07028918
Lead Sponsor Qilu Hospital of Shandong University
Conditions Oral Squamous Cell Carcinoma (OSCC)
Enrollment 35 participants
Start Date 2025-08-30
Primary Completion 2026-08-30 (estimated)
Study Completion 2027-08-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-19